<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050790</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000663409</org_study_id>
    <secondary_id>P30CA016059</secondary_id>
    <secondary_id>MCC-12430</secondary_id>
    <nct_id>NCT01050790</nct_id>
  </id_info>
  <brief_title>Lenalidomide + Azacitidine for Adaptive Immunotherapy -&gt; Auto SCT in Multiple Myeloma</brief_title>
  <official_title>Lenalidomide and Azacitidine for Adaptive Immunotherapy in Multiple Myeloma: Pilot Study of Autologous Lymphocyte Mobilization Following Immuno-modulatory Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer
      cells from growing. Drugs used in chemotherapy, such as azacitidine, work in different ways
      to stop the growth of cancer cells, either by killing the cells or by stopping them from
      dividing. An autologous stem cell transplant may be able to replace blood-forming cells that
      were destroyed by lenalidomide and azacitidine. Giving autologous lymphocytes after the
      transplant may help destroy any remaining cancer cells.

      PURPOSE: This pilot trial is studying how well giving lenalidomide together with azacitidine
      works when followed by autologous stem cell transplant and autologous lymphocyte infusion in
      treating patients with multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the feasibility of mobilizing and infusing autologous lymphocytes (ALI)
           following immunomodulatory therapy comprising azacitidine and lenalidomide in patients
           with multiple myeloma.

      Secondary

        -  Determine the ability to proceed with autologous stem cell transplantation in these
           patients.

        -  Determine the complete response rate at 6 months following transplant in patients
           treated with this regimen.

        -  Determine the progression-free survival and overall survival of patients treated with
           this regimen.

        -  Determine the time to progression in patients treated with this regimen.

        -  Monitor the toxicity of post-autologous stem cell infusion of autologous lymphocytes.

        -  Measure the pre- and post-ALI immune response to cancer testis antigens (CTA)
           (CTA-specific Ig and T-cell repertoire).

        -  Study the expression of CTA in multiple myeloma before and after azacitidine therapy.

      OUTLINE:

        -  Immunomodulatory therapy: Patients receive azacitidine subcutaneously on days 1-5 and
           oral lenalidomide on days 6-21. Treatment repeats every 28 days for up to 3 courses in
           the absence of disease progression or unacceptable toxicity.

        -  Lymphapheresis: Patients undergo autologous lymphocyte harvest on day 22 of courses 2
           and 3.

        -  Autologous stem cell transplantation (ASCT): Patients undergo single or tandem ASCT
           using standard protocols.

        -  Autologous lymphocyte infusion (ALI): Patients undergo ALI approximately 28-60 days
           after ASCT.

      Blood samples are collected at baseline and periodically during study for correlative
      laboratory studies, including CTA-specific immune monitoring by RT-PCR, ELISPOT assays, and
      flow cytometry. Tissue samples from bone marrow aspirates are also collected at baseline,
      during course one, and after course three for CTA expression and methylation studies.

      After completion of study therapy, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment</measure>
    <time_frame>6 months</time_frame>
    <description>Time frame is post 2nd and 3rd cycles of rev/aza and after stem cell transplant engraftment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>16 of 17 patients proceeded to transplant. 6 month CR rate post transplant was 8/16 (50%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as Assessed by NCI CTCAE v3.0</measure>
    <time_frame>6 months</time_frame>
    <description>Time frame includes after stem cell transplant engraftment. Toxicity post ALI infusion: 1 patient grade 1 hypertension 90 min post infusion. Toxicity post Rev maintenance: 1 patient not tolerated, 1 patient dose decreased due to counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression Post Transplant</measure>
    <time_frame>28 months</time_frame>
    <description>Time to progression post transplant: For patients not in Complete Response (CR), progressive disease requires one or more: &gt;25% increase in the level of the serum monoclonal paraprotein(absolute increase of at least 0.5 g/dL); &gt; 25% increase in 24-hour urinary light chain excretion(absolute increase of at least 200m/24 hours). Increase plasma cells in a bone marrow aspirate( absolute increase of at least 10%). Definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of new bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum Ca &gt; 11.5 mg/dL or &gt; 2.65 mmol/L) not attributable to any other cause. All relapse categories require two consecutive assessments made any time before classification as relapse or progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free and Overall Survival</measure>
    <time_frame>1 year to 2 years</time_frame>
    <description>Survival and event-free survival curves (any event of fatality, relapse, acute or chronic GVHD) with Kaplan-Meier curves. The incidence curve for relapse - accounting for the competing risk of fatality - is plotted with step-wise curves. The R statistical software (version 2.15) was used for all time-to-event analyses, with the survival package used for survival curves, and the cmprsk package used for all competing risk curves.
Results: The one-year survival rate is 93.3% (SE = 0.4%), and the two-year survival rate is 86.1% (SE = 0.9%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and Post-ALI Immune Response to Cancer Testis Antigens (CTA)</measure>
    <time_frame>6 months</time_frame>
    <description>Not able to obtain outcome data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTA Expression Before and After Azacitidine Therapy</measure>
    <time_frame>3 months</time_frame>
    <description>Six patients tested have demonstrated CTA up-regulation in either unfractionated bone marrow (n = 4) or CD138+ cells (n = 2). CTA (CTAG1B)-specific T cell response has been observed in all three patients tested and persists following SCT.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Aza Len Lymphapheresis SCT ALI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.</description>
    <arm_group_label>Aza Len Lymphapheresis SCT ALI</arm_group_label>
    <other_name>Vidaza®</other_name>
    <other_name>lenalidomide</other_name>
    <other_name>CC-5013</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with a diagnosis of multiple myeloma, who have residual measurable disease
             (in partial remission or with stable disease) and are eligible to undergo an
             autologous stem cell transplant will be able to participate in this trial; measurable
             disease will comprise of either, quantifiable serum or urinary, M protein or free
             light chains in the presence of a positive immunofixation or bone marrow plasma cells
             &gt; 5%

          -  Patients who have received prior lenalidomide therapy will be eligible if &gt;= partial
             response (PR) was observed on a prior lenalidomide containing regimen and patients did
             not progress while receiving lenalidomide; isolated bone lytic lesions in the absence
             of measurable para-proteins will not be considered measurable disease

          -  A minimum period of two weeks must have elapsed following the prior myeloma therapy;
             this does not include therapy with bisphosphonates

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  No clinical evidence of uncontrolled viral, fungal, bacterial infection

          -  Negative serology for human immunodeficiency virus (HIV)

          -  Serum bilirubin =&lt; 1.5 times upper limit of normal (ULN)

          -  Serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase
             (SGPT) =&lt; 3x ULN

          -  Calculated creatinine clearance &gt;= 60ml/min by Cockcroft-Gault formula; creatinine
             clearance &gt;= 60 ml/min or serum creatinine =&lt; 2.0 mg/dL

          -  Absolute neutrophil count (ANC) &gt;= 1500/uL

          -  Platelet count &gt;= 100,000/ uL

          -  Hemoglobin (Hgb) &gt;= 10 g/dL following recovery from last therapy

          -  Cardiac and pulmonary function adequate for transplant

          -  Ability to sign informed consent

          -  All study participants must be registered into the mandatory RevAssist program, and be
             willing and able to comply with the requirements of RevAssist

          -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
             test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again
             within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7
             days) and must either commit to continued abstinence from heterosexual intercourse or
             begin TWO acceptable methods of birth control, one highly effective method and one
             additional effective method AT THE SAME TIME, at least 28 days before she starts
             taking lenalidomide; FCBP must also agree to ongoing pregnancy testing

          -  Men must agree to use a latex condom during sexual contact with a FCBP even if they
             have had a successful vasectomy

        Exclusion criteria:

          -  Known or suspected hypersensitivity to azacitidine or mannitol

          -  Patients with multiple myeloma refractory to therapy with lenalidomide; progression
             following discontinuation of prior therapy with lenalidomide is allowed as long as
             patients have not failed rechallenge with lenalidomide

          -  Pregnant or breast feeding

          -  Other concomitant malignancies

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form

          -  Concurrent use of other anti-cancer agents or treatments

          -  Known hypersensitivity to thalidomide or lenalidomide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir A. Toor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <results_first_submitted>July 16, 2015</results_first_submitted>
  <results_first_submitted_qc>September 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2015</results_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential patients will be identified at the first BMT consult. They will then be preliminarily screened. If deemed eligible, they will be consented at the second BMT consult. After consent the subject will be officially screened for eligibility as described in the protocol. If eligible they will be enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aza Len Lymphapheresis SCT ALI</title>
          <description>Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Multiple Myeloma in either first or subsequent partial remission with measurable disease, eligible for autologous SCT.</population>
      <group_list>
        <group group_id="B1">
          <title>Aza Len Lymphapheresis SCT ALI</title>
          <description>Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.59" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment</title>
        <description>Time frame is post 2nd and 3rd cycles of rev/aza and after stem cell transplant engraftment.</description>
        <time_frame>6 months</time_frame>
        <population>17 of 17 patients were able to mobilize lymphocytes. 16 of 17 patients had lymphocytes infused post transplant. 1 patient was not able to mobilize stem cells and so did not go to transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>5-azacytidine + Lenalidomide -&gt; Auto Stem Cell Transplant</title>
            <description>azacitidine: 75 mg/sq m daily for 5 days
lenalidomide: 10 mg p.o. daily, Days 6-21</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment</title>
          <description>Time frame is post 2nd and 3rd cycles of rev/aza and after stem cell transplant engraftment.</description>
          <population>17 of 17 patients were able to mobilize lymphocytes. 16 of 17 patients had lymphocytes infused post transplant. 1 patient was not able to mobilize stem cells and so did not go to transplant.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mobilize lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lymphocytes infused post transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not able to mobilize stem cells/no transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Rate at 6 Months</title>
        <description>16 of 17 patients proceeded to transplant. 6 month CR rate post transplant was 8/16 (50%).</description>
        <time_frame>6 months</time_frame>
        <population>1 patient did not proceed to transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>5-azacytidine + Lenalidomide -&gt; Auto Stem Cell Transplant</title>
            <description>azacitidine: 75 mg/sq m daily for 5 days
lenalidomide: 10 mg p.o. daily, Days 6-21</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate at 6 Months</title>
          <description>16 of 17 patients proceeded to transplant. 6 month CR rate post transplant was 8/16 (50%).</description>
          <population>1 patient did not proceed to transplant.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity as Assessed by NCI CTCAE v3.0</title>
        <description>Time frame includes after stem cell transplant engraftment. Toxicity post ALI infusion: 1 patient grade 1 hypertension 90 min post infusion. Toxicity post Rev maintenance: 1 patient not tolerated, 1 patient dose decreased due to counts.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5-azacytidine + Lenalidomide -&gt; Auto Stem Cell Transplant</title>
            <description>azacitidine: 75 mg/sq m daily for 5 days
lenalidomide: 10 mg p.o. daily, Days 6-21</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity as Assessed by NCI CTCAE v3.0</title>
          <description>Time frame includes after stem cell transplant engraftment. Toxicity post ALI infusion: 1 patient grade 1 hypertension 90 min post infusion. Toxicity post Rev maintenance: 1 patient not tolerated, 1 patient dose decreased due to counts.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Toxicity post ALI infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toxicity post Rev maintenance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression Post Transplant</title>
        <description>Time to progression post transplant: For patients not in Complete Response (CR), progressive disease requires one or more: &gt;25% increase in the level of the serum monoclonal paraprotein(absolute increase of at least 0.5 g/dL); &gt; 25% increase in 24-hour urinary light chain excretion(absolute increase of at least 200m/24 hours). Increase plasma cells in a bone marrow aspirate( absolute increase of at least 10%). Definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of new bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum Ca &gt; 11.5 mg/dL or &gt; 2.65 mmol/L) not attributable to any other cause. All relapse categories require two consecutive assessments made any time before classification as relapse or progressive disease.</description>
        <time_frame>28 months</time_frame>
        <population>Progression is collected anytime after transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>5-azacytidine + Lenalidomide -&gt; Auto Stem Cell Transplant</title>
            <description>azacitidine: 75 mg/sq m daily for 5 days
lenalidomide: 10 mg p.o. daily, Days 6-21</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression Post Transplant</title>
          <description>Time to progression post transplant: For patients not in Complete Response (CR), progressive disease requires one or more: &gt;25% increase in the level of the serum monoclonal paraprotein(absolute increase of at least 0.5 g/dL); &gt; 25% increase in 24-hour urinary light chain excretion(absolute increase of at least 200m/24 hours). Increase plasma cells in a bone marrow aspirate( absolute increase of at least 10%). Definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of new bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum Ca &gt; 11.5 mg/dL or &gt; 2.65 mmol/L) not attributable to any other cause. All relapse categories require two consecutive assessments made any time before classification as relapse or progressive disease.</description>
          <population>Progression is collected anytime after transplant.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="4.2" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free and Overall Survival</title>
        <description>Survival and event-free survival curves (any event of fatality, relapse, acute or chronic GVHD) with Kaplan-Meier curves. The incidence curve for relapse – accounting for the competing risk of fatality – is plotted with step-wise curves. The R statistical software (version 2.15) was used for all time-to-event analyses, with the survival package used for survival curves, and the cmprsk package used for all competing risk curves.
Results: The one-year survival rate is 93.3% (SE = 0.4%), and the two-year survival rate is 86.1% (SE = 0.9%).</description>
        <time_frame>1 year to 2 years</time_frame>
        <population>The outcome measure data was collected up to one to two years post transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>5-azacytidine + Lenalidomide -&gt; Auto Stem Cell Transplant</title>
            <description>azacitidine: 75 mg/sq m daily for 5 days
lenalidomide: 10 mg p.o. daily, Days 6-21</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free and Overall Survival</title>
          <description>Survival and event-free survival curves (any event of fatality, relapse, acute or chronic GVHD) with Kaplan-Meier curves. The incidence curve for relapse – accounting for the competing risk of fatality – is plotted with step-wise curves. The R statistical software (version 2.15) was used for all time-to-event analyses, with the survival package used for survival curves, and the cmprsk package used for all competing risk curves.
Results: The one-year survival rate is 93.3% (SE = 0.4%), and the two-year survival rate is 86.1% (SE = 0.9%).</description>
          <population>The outcome measure data was collected up to one to two years post transplant.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>one- year survival rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="92.52" upper_limit="94.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>two-year survival rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1" lower_limit="84.34" upper_limit="87.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>one-year relapse rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="11.13" upper_limit="13.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>two-year relapse rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="17.04" upper_limit="21.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>one-year event free survival rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="86.13" upper_limit="88.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>two-year event free survival rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" lower_limit="64.16" upper_limit="70.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre- and Post-ALI Immune Response to Cancer Testis Antigens (CTA)</title>
        <description>Not able to obtain outcome data.</description>
        <time_frame>6 months</time_frame>
        <population>Not able to obtain outcome data. The lab doing this correlative analysis lost the personnel support to process the samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Aza Len Lymphapheresis SCT ALI</title>
            <description>Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-ALI Immune Response to Cancer Testis Antigens (CTA)</title>
          <description>Not able to obtain outcome data.</description>
          <population>Not able to obtain outcome data. The lab doing this correlative analysis lost the personnel support to process the samples.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CTA Expression Before and After Azacitidine Therapy</title>
        <description>Six patients tested have demonstrated CTA up-regulation in either unfractionated bone marrow (n = 4) or CD138+ cells (n = 2). CTA (CTAG1B)-specific T cell response has been observed in all three patients tested and persists following SCT.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5-azacytidine + Lenalidomide -&gt; Auto Stem Cell Transplant</title>
            <description>azacitidine: 75 mg/sq m daily for 5 days
lenalidomide: 10 mg p.o. daily, Days 6-21</description>
          </group>
        </group_list>
        <measure>
          <title>CTA Expression Before and After Azacitidine Therapy</title>
          <description>Six patients tested have demonstrated CTA up-regulation in either unfractionated bone marrow (n = 4) or CD138+ cells (n = 2). CTA (CTAG1B)-specific T cell response has been observed in all three patients tested and persists following SCT.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTA up-regulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD138+ cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unfractionated bone marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTA (CTAG1B)-specific T cell response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year the subject will be on study and evaluated for adverse events.</time_frame>
      <desc>Medical history and physical before treatment, Days 1, 5 and 22 of the 1st cycle and before cycles 2 and 3, before ALI. Blood for study specific tests drawn before ALI and 2, 4 and 8 weeks after and if relapse occurs. Chest x ray before ALI. Bone marrow Biopsy at baseline and after cycle 3.</desc>
      <group_list>
        <group group_id="E1">
          <title>5-azacytidine + Lenalidomide -&gt; Auto Stem Cell Transplant</title>
          <description>azacitidine: 75 mg/sq m daily for 5 days
lenalidomide: 10 mg p.o. daily, Days 6-21</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE VERSION 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - blood</sub_title>
                <description>Hospitalization.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Hospitalization.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Hospitalization. Grade 3: Requiring more than one drug or more intensive therapy than previously.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <description>Hospitalization. Grade 3, Severe pain; pain or analgesics severely interfering with ADL.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Pack</sub_title>
                <description>Hospitalization. Received radiation therapy with improvement. Grade 3: Severe pain; pain or analgesics severely interfering with ADL.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - Anxiety</sub_title>
                <description>Neurology, Grade 2: Mild mood alteration not interfering with function .</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mental Status</sub_title>
                <description>Neurology. Hospitalization.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>Hospitalization, disease progression and death occurred after 100 days. Grade 5, death.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <description>Grade 3, Symptomatic, interfering with ADL; O2 indicated.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Hospitalization.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE VERSION 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low Hemoglobin</sub_title>
                <description>Grade 2-3.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 2-3.</description>
                <counts group_id="E1" events="27" subjects_affected="11" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Grade 2-3.</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>High Creatinine</sub_title>
                <description>Grade 2-3.</description>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>High AST</sub_title>
                <description>Grade 2-3.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>High ALT</sub_title>
                <description>Grade 2-3.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amir A. Toor, MD, Associate Professor of Medicine</name_or_title>
      <organization>Virginia Commonwealth University/Massey Cancer Center</organization>
      <phone>804-828-4360</phone>
      <email>atoor@mcvh-vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

